C. Gresty

发表

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germlineBRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

A. Italiano, S. Domchek, S. Im, 2019, Poster Discussion Abstracts.

Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

N. Agarwal, K. Abrams, N. Hawkins, 2021, Targeted Oncology.

Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.

F. Saad, G. Gravis, D. Castellano, 2022, The Lancet. Oncology.

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

F. Saad, N. Agarwal, C. Corcoran, 2020, The New England journal of medicine.

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Y. Drew, S. Domchek, Young-Ae Park, 2019, Annals of Oncology.

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.

C. Redfern, N. Clarke, J. Jassem, 2022, The Lancet. Oncology.

Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)

Y. Bang, A. Italiano, S. Domchek, 2018 .

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

N. Agarwal, G. Kramer, M. Carducci, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

M. Gore, Y. Drew, S. Domchek, 2018, Gynecologic Oncology.

610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

N. Agarwal, C. Corcoran, O. Sartor, 2020, Annals of Oncology.

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

A. Italiano, S. Domchek, Young-Ae Park, 2019, Annals of Oncology.

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

S. Domchek, Sang-We Kim, F. Barlesi, 2017 .

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.

Y. Bang, S. Domchek, B. Kaufman, 2019, Journal of Clinical Oncology.

Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone.

F. Saad, C. Redfern, N. Clarke, 2019, Journal of Clinical Oncology.